SEC Form 4 · accession 0001209191-17-050044
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geert Cauwenbergh
Officer — President & CEO · Director
Period of report
Aug 24, 2017
Accepted (ET)
Aug 24, 2017 · 11:55 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Aug 24, 2017 | P | 4,900 | $0.545 | A | 127,483 | D | |
| Common stock, $0.0001 par value | Aug 24, 2017 | P | 4,361 | $0.55 | A | 131,844 | D | |
| Common stock, $0.0001 par value | Aug 24, 2017 | P | 739 | $0.56 | A | 132,583 | D | |
| Common stock, $0.0001 par value | holding | — | — | — | 4,500 | I | By spouse | |
| Common stock, $0.0001 par valueF1 | holding | — | — | — | 450 | I | By son |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares held by the Reporting Person's son. The Reporting Person disclaims beneficial ownership of such shares and this report shall not constitute an admission of beneficial ownership.